Novel PET tracers and their future use in assessment of response to treatment

Clinical trials for rare tumour types

Regorafenib effective for GISTs that progress due to resistance to approved targeted therapies

ASCO 2012: Advances in myeloma

President's overview of ASCO 2012

Afatinib delays progression of advanced lung adenocarcinomas

Costly drugs versus paclitaxel as first line therapy for locally advanced or metastatic breast cancer

Regorafenib effective for GISTs that progress due to resistance to approved targeted therapies

Increased progression-free survival in advanced lung cancer with afatinib

Prognostic biomarkers and next generation genomic sequencing

Bringing together the resources of Eastern and Western European institutes

Recent developments in neoadjuvant therapy